Ga-68-PSMA-11
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Trial Timeline
Jul 27, 2021 → Apr 14, 2022
NCT ID
NCT05744115About Ga-68-PSMA-11
Ga-68-PSMA-11 is a phase 3 stage product being developed by Telix Pharmaceuticals for Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05744115. Target conditions include Prostate Cancer, Prostate Adenocarcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05744115 | Phase 3 | Terminated |
Competing Products
20 competing products in Prostate Cancer